LEGENDARY ACQUITY PERFORMANCE - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

LEGENDARY ACQUITY PERFORMANCE.
AT EVERY LEVEL FOR EVERY LAB.

In 2004, ACQUITY UPLC® gave future-focused labs the highest level of chromatographic performance the world had ever seen. Then came a dramatically greater demand for better results in less time. And UPLC® quickly went from leading-edge luxury to global necessity.

Today, Waters meets the ever-growing demand for higher levels of resolution and sensitivity with an ever-growing family of ACQUITY® Systems. That means for virtually any application, in every analytical lab, all over the world, there’s an ACQUITY System that’s right for you. To find the one that’s right for your lab, visit waters.com/ACQUITY.

Corporate Headquarters
Waters Corporation
34 Maple Street
Milford, MA 01757
T: 508-478-2000 or 1-800-252-4752
F: 508-872-1990
www.waters.com

European Headquarters
Waters S.A.S.
BP 608
78056 Saint-Quentin
En Yvelines Cedex, France
T: 33 1 30 48 72 00
F: 33 1 30 48 72 01
www.waters.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here